A Phase 3 clinical trial involving tirzepatide was updated on August 21, 2026. The study, registered as NCT06937099, is titled "Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight."
The trial is currently listed with a status of recruiting. It is designed to evaluate mirikizumab and tirzepatide together in adults who have moderately to severely active Crohn's disease along with obesity or overweight.
This is a Phase 3 study, according to the trial registry entry. No results have been posted for this trial as of this update. The event data does not include information on outcomes, safety findings, or efficacy conclusions.
Tirzepatide is currently an approved compound. This particular trial explores its use in combination with mirikizumab within a specific patient population defined by Crohn's disease status and body weight classification.
Readers interested in the study details can consult the official trial registration for further information on enrollment criteria and trial design. For general background on this compound, refer to the compound overview.